Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics

Summary

Atypical antipsychotic drugs are commonly used to treat psychiatric illnesses but they are significantly associated with side effects including acute dystonia, akathisia, parkinsonism (rigidity and tremor), tardive dyskinesia, bradycardia, hypotension, impotence, sleepiness, seizures, severe dreams or nightmares, and hyperprolactinaemia. Vitamin D and E, have been the focus of much research in the past fifteen years, which has revealed multiple roles in the development and function of the body. According to mounting data from the domains of epidemiology and neuroscience, vitamin D and E deficiency have been related to a number of neuropsychiatric issues as well as neurodegenerative diseases. Additionally, antioxidants like vitamin E help to prevent inflammation and highly reactive oxygen molecules from damaging normal cells. The use of vitamin E and D supplements has been suggested to improve the overall outcomes of psychiatric illnesses and neurological diseases. However, the synergistic effect of vitamins E and D in reducing the risk of the adverse effects associated with atypical antipsychotics and improvement in psychiatric illness is not well understood. Therefore, this study was designed to investigate the potential synergistic effect of vitamin E and D supplements for reducing the adverse effects associated with atypical antipsychotics.

Conditions

• Antipsychotics and Neuroleptics Toxicity

Interventions

DRUG

Risperidone

Antipsychotic Agent

DRUG

Olanzapine

Antipsychotic Agent

DRUG

Quetiapine

Antipsychotic Agent

DRUG

Risperidone and Vitamin D and Vitamin E

vitamin

DRUG

Olanzapine and Vitamin D and Vitamin E

vitamin and Antipsychotic agent

DRUG

Quetiapine and Vitamin D and Vitamin E

Vitamin and Antipsychotic agents

Sponsors & Collaborators

• Dr Rabia Arshad

  lead OTHER

Principal Investigators

• DR MUHAMMAD ABID, MBBS · BMSI, JINNAH POST GRADUATE MEDICAL CENTRE,Karachi,Pakistan

Study Design

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

20 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-01-01

Primary Completion

2021-06-01

Completion

2021-06-10

Countries

• Pakistan

Study Locations